CD19 is a transmembrane glycoprotein that contains two extracellular immunoglobulin-like domains. CD19 is present in both benign and malignant B-cells and is considered to be the most reliable surface marker of this lineage over a wide range of maturational stages. In normal lymphoid tissue, CD19 is observed in germinal centers, in mantle zone cells, and in scattered cells of the inter-follicular areas. Anti-CD19 exhibits an overall immunoreactivity patte similar to those of the antibodies against CD20 and CD22. However, in contrast to CD20, expression of CD19 is continuous throughout B-cell development and through terminal differentiation of B-cells into plasma cells. Anti-CD19 positivity is seen in the vast majority of B-cell neoplasms commonly at a lower intensity than normal B-cell counterparts. Plasma cell neoplasms are nearly always negative, as are T-cell neoplasms.
Formulation
1 mg/ml in 1X PBS; BSA free, sodium azide free
Host
Mouse
Immunogen Region
A recombinant human partial protein (amino acids 96-281) was used as the immunogen for the CD19 antibody.
Isotype
Mouse IgG1, kappa
Species Reactivity
Human
Note
Optimal dilution of the antibody should be determined by the researcher.
Uniprot
P15391
Format
Purified
Purity
Protein G affinity chromatography
Storage
Store the CD19 antibody at 2-8oC (with azide) or aliquot and store at -20oC or colder (without azide).
Applications
ELISA, FACS, IHC-P
Description
ELISA (order BSA-free format for coating),Flow cytometry: 1-2ug/million cells in 0.1ml,Immunohistochemistry (FFPE): 1-2ug/ml